The NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) The Ishares Nasdaq Biotechnology Index Fund Begins Trading On The NASDAQ Stock Market

The NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) Barclays Global Investors Transferred the Listing to NASDAQ

NEW YORK, Sept. 23, 2008 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced that the iShares(r) Nasdaq Biotechnology Index Fund (Nasdaq:IBB) began trading today on The NASDAQ Stock Market(r) (NASDAQ(r)). Barclays Global Investors (BGI), one of the world's largest institutional asset managers and Exchange Traded Funds (ETF) managers, transferred the fund to NASDAQ from the American Stock Exchange.

"We are delighted with BGI's decision to list the iShares Nasdaq Biotechnology Index Fund on NASDAQ," said John Jacobs, Executive Vice President, NASDAQ OMX Global Financial Products. "NASDAQ is the natural venue for the fund and we are thrilled it is now listed alongside the companies that comprise the index upon which the fund is based, the NASDAQ Biotechnology Index."

The iShares Nasdaq Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index.

The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.

NASDAQ is the most liquid U.S. market for ETFs, capturing 36.9% of all U.S. ETF volume in August. Average daily matched share volume in August was a record 458 million, more than any other U.S. exchange.

Through NASDAQ OMX Global Financial Products (GFP), NASDAQ OMX(sm) is engaged in the design, development, calculation, dissemination, licensing, and marketing of NASDAQ OMX indexes. GFP specializes in the development of indexes focusing on NASDAQ OMX's brand themes of innovation, technology, growth, and globalization. NASDAQ OMX indexes are the basis of 24 ETFs worldwide with $24.5 billion under management. The NASDAQ-100 Index(r) alone is the basis of more than 600 investment products in more than 30 countries. For more information about NASDAQ OMX indexes, visit www.nasdaq.com/indexes.

For more information about the NASDAQ ETF Market, please contact Richard Keary, NASDAQ New Listings, at +212.401.8903 or richard.keary@nasdaqomx.com or NASDAQ Market Sales at 800.846.0047 or Sales@NASDAQOMX.com.

For more information about the The iShares Nasdaq Biotechnology Index Fund, please visit http://us.ishares.com/product_info/fund/overview/IBB.htm?qt=IBB.

About NASDAQ OMX

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, and with over 3,900 companies, it is number one in worldwide listings among major markets. NASDAQ OMX Group offers multiple capital raising solutions to companies around the globe, including its U.S. listings market; the OMX Nordic Exchange, including First North; and the 144A PORTAL Market. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and ETFs. NASDAQ OMX Group technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. OMX Nordic Exchange is not a legal entity but describes the common offering from NASDAQ OMX Group exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit www.nasdaqomx.com.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein may contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about NASDAQ OMX's products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to, factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

NASDAQ(r) and NASDAQ Biotechnology Index(r) are registered trademarks of The NASDAQ OMX Group, Inc. (which with its affiliates and subsidiaries is collectively "NASDAQ OMX") and are licensed for use by Barclays Global Investors. The iShares NASDAQ Biotechnology Fund has not been passed on by NASDAQ OMX as to its legality or suitability. The iShares NASDAQ Biotechnology Fund is not issued, endorsed, or sold by NASDAQ OMX. NASDAQ OMX MAKES NO WARRANTIES AND BEARS NO LIABILITY WITH RESPECT TO THE ISHARES NASDAQ BIOTECHNOLOGY FUND.

NASDAQ OMX makes no recommendation to buy or sell any security. Investors should undertake their own due diligence before investing.

NDAQG

CONTACT:

NASDAQ OMX Media Contact: Wayne Lee +1.301.978.4875 Wayne.D.Lee@NASDAQOMX.Com

The NASDAQ OMX Group, Inc.

http://ir.nasdaq.com/

ISIN: US6311031081

Stock Identifier: NYS.NDAQ